India’s Sun Pharma Hunts For Bargains Amidst Financial Crisis
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - India's Sun Pharmaceutical reported a 135 percent jump in second-quarter net profit as it said it was eyeing more acquisition possibilities with the global financial crisis making valuations of generic companies more attractive
You may also be interested in...
Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business
MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount
Sun Pharma Buys Chattem Chemicals To Augment Its Controlled Substances Business
MUMBAI - The global economic downturn is throwing up acquisition possibilities for Indian pharmaceutical companies. India's Sun Pharma has lapped up U.S. based Chattem Chemicals, a registered narcotic API importer and producer based in Chattanooga, Tenn., for an undisclosed amount
After Ranbaxy, U.S. FDA Hauls Up Caraco Pharma for QC Issues; May Withhold Future Drug Approvals
MUMBAI - U.S. FDA issued a warning letter to Caraco Pharmaceuticals, a subsidiary of India's Sun Pharmaceuticals, after the drug regulator found quality control lapses at its Detroit facilities, Curaco announced Nov. 3. U.S. FDA said the QC lapses conflicted with the company's standard operating procedures